This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents. Top assignee: Eli Lilly and Company. Active years: 2023-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2024
Title: David Bradley Woodward: Innovator in Therapeutic Applications of Dulaglutide
Introduction
David Bradley Woodward is a notable inventor based in Fishers, Indiana, with a focus on therapeutic innovations in the field of diabetes treatment. He holds two patents that contribute significantly to the management of type 2 diabetes mellitus (T2DM) and its associated cardiovascular risks. His work is instrumental in advancing medical treatments that improve patient outcomes.
Latest Patents
Woodward's latest patents include innovative methods for utilizing dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The first patent addresses therapeutic uses of dulaglutide, specifically aimed at reducing the risk of major adverse cardiovascular events in T2DM patients who have multiple cardiovascular risk factors. This invention is particularly relevant for patients without established cardiovascular disease or those who do have it. The second patent focuses on methods of using and compositions containing higher doses of dulaglutide, enhancing the therapeutic options available for patients.
Career Highlights
David Bradley Woodward is associated with Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to innovation in diabetes care. His contributions to the field have been recognized through his patents, which reflect his dedication to improving treatment methodologies for diabetes patients.
Collaborations
Woodward has collaborated with notable colleagues, including Jeffrey S. Riesmeyer and David Andrew Cox, who share a commitment to advancing medical science and improving patient care through innovative research and development.
Conclusion
David Bradley Woodward's work exemplifies the impact of innovation in the medical field, particularly in diabetes treatment. His patents on dulaglutide not only enhance therapeutic options but also aim to improve the quality of life for patients with type 2 diabetes. His contributions are a testament to the importance of research and collaboration in the pursuit of medical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile